Azitra, Inc. (AZTR) fundamentals score
Azitra is a pioneer in genetically engineering bacteria for therapeutic use in dermatology. Its goal is to leverage its platforms and internal microbial library bacterial strains to create new therapeutics that are either engineered living organisms or engineered proteins or peptides to treat skin diseases.
Pharmaceutical Preparations · Healthcare · Listed on NYSE
Overall: 2.2 out of 10, Unhealthy fundamentals
- Growth: 3.1/10
- Profitability: 1.0/10
- Financial health: 4.1/10
- Earnings quality: 1.1/10
- Valuation: 1.5/10
Scores are calculated from Azitra, Inc.’s SEC filings, using the 12 months through 2024-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10